Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations

Mufti, G J; Hamblin, Terry J.; Oscier, David; Johnson, Sharron

doi:10.1182/blood.v62.5.1142.1142

Cited by 78 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of interest is that all of our patients, including those with t(8; 14)(q24,q32), had histology of the non-Burkitt's subtype. However, t( 14;18)(q32;q21) is most often reported in association with follicular subtypes of NHL, being found in up to 70 to 80% of these histologies [36,37] but has also been reported in isolated cases of common acute lymphoblastic leukemia with pre B-cell features [38,39], and in cases of diffuse lymphoma of follicular center origin and DSNCL of the non-Burkitt's subtype [36]. In up to half of cases of diffuse lymphoma with the t( 14;18), transformation from a follicular histology has been described [ 4 W 2 ] .…”

Section: Diffuse Small Non-cleaved Cell Lymphoma 301mentioning

confidence: 99%

Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults

Morrison¹,

Frizzerà²,

Arthur³

et al. 1994

American J Hematol

View full text Add to dashboard Cite

Most reports of prognosis and therapy in diffuse small non-cleaved cell lymphoma (DSNCL), an aggressive high-grade non-Hodgkin's lymphoma (NHL) which appears to be of two histopathologic subtypes, have included predominantly a pediatric population and very few adults. We studied 20 newly diagnosed, previously untreated adults with DSNCL. Three patients had Ann Arbor Stage I disease, five Stage II, and 12 Stage IV. Bone marrow involvement was present in seven of 20 (35%) patients; no patient had central nervous system involvement at diagnosis. Clonal chromosomal abnormalities were found on cytogenetic analysis of all 12 cases studied. Ten patients had specific recurring translocations, including t(8;14) (q23;q32) (five patients), t(14;18) (q32;q21) (four patients), and t(2;8) (p12;q24) (one patient). Induction chemotherapy with the COMP regimen (cyclophosphamide, vincristine, methotrexate, and prednisone) or a variant schedule of the same drugs resulted in complete remission for 13 patients (65%), and partial remission for 5 patients (25%). Clinical characteristics predictive of a favorable response to induction therapy included Stage I or II disease, a normal lactic dehydrogenase (LDH), and performance status (PS) of 0 or 1. Remission duration ranged from two to 125+ (median 37+) months. Survival ranged from one to 126+ (median 23) months; ten patients (50%) remain alive, nine with no active disease. Factors predictive of longer survival included achievement of a complete remission with induction therapy, a normal LDH, and PS 0 or 1. As in children with DSNCL, long-term disease-free survival may be achieved in adults with combination chemotherapy.

show abstract

Section: Diffuse Small Non-cleaved Cell Lymphoma 301mentioning

confidence: 99%

Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults

Morrison¹,

Frizzerà²,

Arthur³

et al. 1994

American J Hematol

View full text Add to dashboard Cite

show abstract

“…The presence of an 8; 14 (MYC-IGH) chromosome translocation as well as a 14; 18 translocation in certain aggressive human B lymphoid neoplasms (e.g. Mufti et al, 1983) was also suggestive of a synergistic relationship between these two oncogenes.…”

Section: Introductionmentioning

confidence: 96%

Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival.

et al. 1996

View full text Add to dashboard Cite

Mice expressing both a bcl‐2 and a myc transgene within the B lymphoid cell compartment invariably develop novel immature haemopoietic tumours. The likely cell of origin of these tumours was identified by a common pattern of cell surface marker expression on a subset of cells comprising approximately 1% of normal mouse bone marrow. The bcl‐2‐myc tumour cells could be induced to differentiate into either B lymphocytes or macrophages in culture with certain cytokines and feeder cells. Analysis of their progression into the B lymphoid lineage revealed that Igk locus transcription can precede Igh as well as Igk rearrangement. Surprisingly, the undifferentiated tumour cells died rapidly in culture, even in the presence of multiple cytokines, but they proliferated on monolayers of stromal cells derived from haemopoietic tissues. Thus, even with Bcl‐2 levels that protect more differentiated cells, these immature bi‐potential progenitor cells require a stromal‐induced signal for survival. These results provide insight into the process of lineage commitment and suggest new levels of control of cell survival during early steps in haemopoietic development.

show abstract

“…Burkitt lymphoma, on the other hand, is a highly aggressive lymphoma where translocation involving MYC is a constant genetic feature (2). Only rarely does a high-grade B-cell lymphoma exhibit a simultaneous t(14;18) and a rearrangement involving MYC (3)(4)(5)(6)(7)(8)(9)(10). Lymphoid neoplasms with these dual translocations have an aggressive course and are generally associated with a very poor prognosis (11).…”

mentioning

confidence: 99%

U‐2973, a novel B‐cell line established from a patient with a mature B‐cell leukemia displaying concurrent t(14;18) and MYC translocation to a non‐IG gene partner

Boström

Leuchowius

Hallböök

et al. 2008

European J of Haematology

View full text Add to dashboard Cite

B-cell lymphomas/leukemias with simultaneous t(14;18)(q32;q21) and MYC rearrangements have recently been shown to constitute a separate diagnostic entity, presenting with a rapid clinical course and a very poor prognosis. We describe the establishment of an Epstein-Barr virus negative cell line, designated U-2973, from a male patient with a de novo aggressive B-cell lymphoma/leukemia and very high peripheral blast cell count. Flow cytometry of bone marrow cells and U-2973 displayed a mature B-cell phenotype, and immunostaining showed expression of MYC and BCL2. IG gene rearrangement data were consistent with a lymphoid neoplasm of germinal centre derivation. Cytogenetic studies using conventional G-banding, fluorescent in situ hybridization, spectral karyotyping and single nucleotide polymorphism array demonstrated a complex karyotype with both a t(14;18) and double translocations between MYC and a non-IG gene partner located at chromosome 12p12.1.

show abstract

Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations

Cited by 78 publications

References 16 publications

Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults

Prognostic factors for therapeutic outcome of diffuse small non‐cleaved cell lymphoma in adults

Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival.

U‐2973, a novel B‐cell line established from a patient with a mature B‐cell leukemia displaying concurrent t(14;18) and MYC translocation to a non‐IG gene partner

Contact Info

Product

Resources

About